Brief: Biodesix Advances Two Complementary Approaches To Molecular Residual Disease (Mrd) Monitoring
24/09/2026 11:04
BRIEF-Biodesix Advances Two Complementary Approaches To Molecular Residual Disease (Mrd) Monitoring Sept 24 (Reuters) - Biodesix Inc BDSX.O:
BIODESIX ADVANCES TWO COMPLEMENTARY APPROACHES TO MOLECULAR RESIDUAL DISEASE (MRD) MONITORING
Source text: ID:nGNX5Q2YmJ
Further company coverage: BDSX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biodesix
See all newsBrief: Biodesix - Adds Digital Diagnostics To Lung Diagnostics Strategy
Brief: Biodesix Advances Two Complementary Approaches To Molecular Residual Disease (Mrd) Monitoring
Biodesix Inc reports results for the quarter ended June 30 - Earnings Summary
Biodesix Q2 revenue rises 34%, beats analyst estimates
Brief: Biodesix Q2 Net Income USD -7.273 Million